The FDA issued a drug shortage alert for the Asmanex Twisthaler 110 mcg mometasone furoate inhalation Powder, 30 inhalation units, as of April 26, 2012. According to the FDA web site, the shortage is due to manufacturing delays and the expected duration is unknown.
The 110 mcg dose Asmanex Twisthaler is recommended for the treatment of asthma in children ages 4-11 years of age. The product is also available in a 220 mcg dose recommended for adults and children 12 and over, which is apparently unaffected by the manufacturing delays.
Asmanex Twisthaler is manufactured by Schering, a subsidiary of Merck.
